Skip to ContentSkip to Navigation
About usNews and EventsNews articles

€ 500,000 grant for research into prostate cancer

03 July 2012

Three researchers from the UMCG have been awarded a grant of € 500,000 by the Dutch Cancer Society [KWF Kankerbestrijding] for research into a new treatment for prostate cancer. The focus of their research will be on boosting the ‘chemo vaccination effect’, whereby after chemotherapy, dead cancer cells help to generate an immunoreaction to living cancer cells. The project will contribute to the ongoing search for better vaccines for treating or preventing prostate cancer and other forms of cancer.

Prostate cancer is one of the most common types of cancer among men. The number of cases has risen steeply over the past years. If detected in time, prostate cancer can be cured. Surgical removal of the affected prostate is one of the treatment options, but this is a complex procedure that can lead to impotence and incontinence. However, if it has spread, the disease is almost impossible to treat and life expectancy is short.

Researchers recently discovered that the dying and dead cancer cells resulting from treatment using a certain form of chemotherapy can prompt an immunoreaction to the cancer cells that are still active. Unfortunately, this reaction (also known as the ‘chemo vaccination effect’) is too weak to suppress the disease. The aim of this research is to find ways of boosting this effect. To achieve this, it is important that certain processing cells (dendrites) in the immune system become more adept at finding the dead and dying cancer cells so that they can consume and process them more effectively.

Bearing this in mind, researchers Wijnand Helfrich and Edwin Bremer (Surgical Oncology) and oncological urologist Igle Jan de Jong have developed new recombinant protein molecules that are able to deliver certain ‘immune boosting’ signals to the surface of prostate cancer cells selectively. One of these signals is a so-called ‘eat me’ signal. Delivering this signal to cancer cells encourages the dendritic cells already present to up their game. In addition, immunological ‘bait’ is supplied in and around the prostate cancer cells to entice more dendrites towards these prostate cancer cells.

The drug study will initially be carried out in the UMCG laboratories. If the results are encouraging, the researchers will decide whether the drugs they have developed can be adapted for use in patient care. The entire study, which lasts 4 years, will take place in the UMCG.

Note for editors

More information is available from the press information officers at the UMCG, tel. +31 (0)50 361 22 00.

Last modified:15 September 2017 3.29 p.m.
printView this page in: Nederlands

More news

  • 11 July 2019

    Major companies’ annual reports too vague about climate impact

    Many major Dutch companies publish extensive information about climate impact in their annual reports. However, very few companies provide concrete, detailed information about their own CO2 emissions, the impact of climate change on their business...

  • 08 July 2019

    Zeven RUG-projecten krijgen financiering via de NWA Ideeëngenerator

    De NWO heeft aan 37 out-of-the-box onderzoeksideeën financiering toegekend vanuit de Ideeëngenerator. Een belangrijk kenmerk van de projecten is een mogelijke maatschappelijke impact. Elk van de onderzoekers krijgt 50.000 euro beschikbaar om met samen...

  • 08 July 2019

    UG permanently closes Yantai project

    The University of Groningen (UG) has permanently closed the project aimed at creating a branch campus in Yantai. Discussions were held with China Agricultural University, the city of Yantai and the Province of Shandong.